Urologix sets early US launch for Targis
This article was originally published in Clinica
Urologix has brought forward the US launch date for its microwave system for the treatment of benign prostatic hyperplasia (BPH) to the middle of the fourth quarter, due to the rapidity of the FDA's review. FDA approval to market Targis was received only 180 days after filing.
You may also be interested in...
Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.
Guidelines for health care providers could help prevent shortages as demand for possible treatments surge, groups say. Stakeholders also argue “Buy America” executive order would hamper drug access.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.